Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan 17;4(1):100908.
doi: 10.1016/j.xcrm.2022.100908.

Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer

Gayathri Anandappa  1 , Michael J Overman  2
Affiliations
Comment

Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer

Gayathri Anandappa et al. Cell Rep Med. .

Abstract

In a recent issue of Cancer Cell, Amodio and colleagues report an interesting method of modulating immunosurveillance in colorectal tumors with DNA mismatch repair (MMR) heterogeneity.1 By pharmacologically enriching the MMR deficient (MMRd) component using 6-thioguanine, they demonstrate improved tumor control in murine models.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M.J.O. has management/advisory or consulting relationships with Simcere Pharmaceutical, Gritstone, Phanes Therapeutics, Takeda Pharmaceuticals, Pfizer, Merck, Glaxosmithkline, Nouscom, Tempus, Roche, and Bayer.

Comment on

References

    1. Amodio V., Lamba S., Chilá R., Cattaneo C.M., Mussolin B., Corti G., Rospo G., Berrino E., Tripodo C., Pisati F., et al. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer Cell. 2022;41:196–209. doi: 10.1016/j.ccell.2022.12.003. - DOI - PMC - PubMed
    1. Jiricny J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 2006;7:335–346. doi: 10.1038/nrm1907. - DOI - PubMed
    1. Andre T., Lonardi S., Wong K.Y.M., Lenz H.J., Gelsomino F., Aglietta M., Morse M.A., Van Cutsem E., McDermott R., Hill A., et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann. Oncol. 2022;33:1052–1060. doi: 10.1016/j.annonc.2022.06.008. - DOI - PubMed
    1. Chapusot C., Martin L., Bouvier A.M., Bonithon-Kopp C., Ecarnot-Laubriet A., Rageot D., Ponnelle T., Laurent Puig P., Faivre J., Piard F. Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas. Br. J. Cancer. 2002;87:400–404. doi: 10.1038/sj.bjc.6600474. - DOI - PMC - PubMed
    1. Hechtman J.F., Rana S., Middha S., Stadler Z.K., Latham A., Benayed R., Soslow R., Ladanyi M., Yaeger R., Zehir A., et al. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Mod. Pathol. 2020;33:871–879. doi: 10.1038/s41379-019-0414-6. - DOI - PMC - PubMed